Daphne Karydas Sells 3,000 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Director Daphne Karydas sold 3,000 shares of the stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $28.58, for a total transaction of $85,740.00. Following the completion of the transaction, the director owned 6,200 shares in the company, valued at $177,196. This represents a 32.61% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Mineralys Therapeutics Price Performance

Shares of MLYS stock opened at $28.02 on Friday. The firm’s 50 day moving average price is $27.12 and its two-hundred day moving average price is $27.11. The company has a debt-to-equity ratio of 0.18, a quick ratio of 34.46 and a current ratio of 34.46. Mineralys Therapeutics, Inc. has a 52-week low of $22.30 and a 52-week high of $47.65. The stock has a market cap of $2.48 billion, a PE ratio of -6.61 and a beta of 0.68.

Mineralys Therapeutics (NASDAQ:MLYS) last issued its earnings results on Wednesday, August 12th. The company reported ($2.85) EPS for the quarter, missing the consensus estimate of ($0.55) by ($2.30). As a group, analysts forecast that Mineralys Therapeutics, Inc. will post -4.45 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on MLYS shares. Wall Street Zen cut Mineralys Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, August 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Mineralys Therapeutics in a research note on Friday, July 17th. Jefferies Financial Group reiterated a “hold” rating on shares of Mineralys Therapeutics in a research report on Monday, June 1st. HC Wainwright restated a “buy” rating on shares of Mineralys Therapeutics in a report on Monday, June 1st. Finally, Zacks Research raised shares of Mineralys Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Friday, September 11th. Five equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Mineralys Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $48.80.

Hedge Funds Weigh In On Mineralys Therapeutics

Several institutional investors have recently modified their holdings of MLYS. Timothy G. Youngquist 2020 Irrevocable Trust acquired a new position in shares of Mineralys Therapeutics in the second quarter valued at approximately $2,721,000. TimesSquare Capital Management LLC acquired a new stake in shares of Mineralys Therapeutics during the second quarter worth $6,363,000. Bank of America Corp DE lifted its position in Mineralys Therapeutics by 11.5% in the 1st quarter. Bank of America Corp DE now owns 1,100,372 shares of the company’s stock valued at $29,809,000 after acquiring an additional 113,092 shares in the last quarter. Man Group plc acquired a new position in Mineralys Therapeutics in the 2nd quarter worth $1,609,000. Finally, Artia Global Partners LP lifted its holdings in shares of Mineralys Therapeutics by 143.5% in the fourth quarter. Artia Global Partners LP now owns 137,800 shares of the company’s stock valued at $5,001,000 after purchasing an additional 81,200 shares in the last quarter. Institutional investors own 84.46% of the company’s stock.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cardiovascular and kidney-related diseases. The company’s research is centered on conditions associated with excess aldosterone activity, including uncontrolled and resistant hypertension.

Mineralys’ lead investigational product is lorundrostat, also known as MLS-101, an oral, highly selective aldosterone synthase inhibitor. The company is evaluating lorundrostat in clinical studies as a potential treatment for patients whose blood pressure remains inadequately controlled despite existing therapy.